关于《左甲状腺素新旧剂型：数百万患者能否转换使用？》的评论 - Suppr

Comment on: "Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?".

作者信息

Nicolas Patrick

机构信息

Service de Biochimie, Unité de Pharmacologie Bioclinique, Centre Hospitalier Universitaire Avicenne (APHP), 125 Route de Stalingrad, 93009, Bobigny Cedex, France.

出版信息

Clin Pharmacokinet. 2019 Jul;58(7):959-960. doi: 10.1007/s40262-019-00778-w.

DOI:10.1007/s40262-019-00778-w

PMID:31161454

Abstract

摘要

相似文献

Comment on: "Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?".

Clin Pharmacokinet. 2019 Jul;58(7):959-960. doi: 10.1007/s40262-019-00778-w.

Comment on "Levothyrox New and Old Formulations: Are They Switchable for Millions of Patients?".

Clin Pharmacokinet. 2020 May;59(5):655-657. doi: 10.1007/s40262-020-00887-x.

Comment on: "Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?".

Clin Pharmacokinet. 2019 Jul;58(7):965-966. doi: 10.1007/s40262-019-00779-9.

Comment on "Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?".

Clin Pharmacokinet. 2020 Feb;59(2):281-282. doi: 10.1007/s40262-019-00850-5.

Comment on "Levothyrox New and Old Formulations: Are They Switchable for Millions of Patients?".

Clin Pharmacokinet. 2019 Jul;58(7):969-971. doi: 10.1007/s40262-019-00785-x.

Comment on: Levothyrox New and Old Formulations: Are They Switchable for Millions of Patients?

Clin Pharmacokinet. 2019 Jul;58(7):977-978. doi: 10.1007/s40262-019-00784-y.

Comment on: "Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?".

Clin Pharmacokinet. 2019 Oct;58(10):1351-1352. doi: 10.1007/s40262-019-00814-9.

Author's Reply to Trechot: "Comment on Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?".

Clin Pharmacokinet. 2019 Jul;58(7):979-980. doi: 10.1007/s40262-019-00787-9.

Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?".

Clin Pharmacokinet. 2019 Jul;58(7):973-975. doi: 10.1007/s40262-019-00786-w.

Authors' Reply to Coste et al.: "Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?".

Clin Pharmacokinet. 2019 Jul;58(7):967-968. doi: 10.1007/s40262-019-00780-2.

引用本文的文献

Comment on "Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology".

Eur J Drug Metab Pharmacokinet. 2023 Mar;48(2):213-215. doi: 10.1007/s13318-022-00814-4. Epub 2023 Jan 21.

Pharmacokinetics and Generic Drug Switching: A Regulator's View.

Clin Pharmacokinet. 2020 Sep;59(9):1065-1069. doi: 10.1007/s40262-020-00909-8.

Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands.

Clin Transl Sci. 2020 May;13(3):599-607. doi: 10.1111/cts.12746. Epub 2020 Feb 12.

Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?".

Clin Pharmacokinet. 2020 Feb;59(2):273-275. doi: 10.1007/s40262-019-00849-y.

Authors' Reply to Nicolas: "Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?".

Clin Pharmacokinet. 2019 Jul;58(7):961-963. doi: 10.1007/s40262-019-00781-1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Comment on: "Levothyrox New and Old Formulations: Are they Switchable for Millions of Patients?".

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献